Danish Construction Stock News

In January 2026, Ørsted welcomed the newly signed Joint Offshore Wind Investment Pact and the North Sea Wind Pact, which aim to coordinate offshore wind deployment across Europe’s North Seas and support large-scale clean energy development. By targeting up to 15 gigawatts of new offshore capacity per year and seeking more predictable investment frameworks, these agreements could materially reshape how offshore wind projects are planned, financed, and operated across the region. We’ll now...

Amid renewed trade and geopolitical uncertainty, the pan-European STOXX Europe 600 Index recently ended 0.98% lower, reflecting a broader decline across major European stock indexes. Despite this downturn, opportunities may exist for investors seeking stocks that could be trading below their estimated value, particularly in sectors where business activity remains positive and confidence is on the rise. Identifying undervalued stocks often involves looking at companies with strong fundamentals...

In January 2026, Genmab reported that worldwide 2025 net trade sales of DARZALEX, as reported by Johnson & Johnson, reached US$14.35 billion, generating ongoing royalty revenue for Genmab, and released positive topline Phase 3 EPCORE DLBCL-1 results showing epcoritamab monotherapy improved progression-free survival in relapsed or refractory DLBCL versus standard regimens. The combination of a very large, royalty-generating DARZALEX franchise and clinically meaningful Phase 3 data for...

Vestas Wind Systems (CPSE:VWS) is back in focus after European countries agreed on plans for 100 GW of shared offshore wind capacity in the North Sea, and Vestas shares rose 5.2% on the news. See our latest analysis for Vestas Wind Systems. The North Sea pact has arrived on top of a strong run in Vestas’ shares, with a 90 day share price return of 46.61% and a 1 year total shareholder return of 103.98% from a starting point that had seen weaker multi year outcomes. Recent gains, including a...

A.P. Møller - Mærsk has resumed part of its Red Sea–Suez Canal sailings with conditional routing, while also appointing Charles van der Steene as Regional Managing Director for the Indian Subcontinent, Middle East & Africa from 1 January 2026 and progressing a share buy-back program of up to DKK 14.40 billion announced in February 2025. Together, these developments highlight Maersk’s mix of operational risk management, regional leadership continuity and capital return decisions at a time of...

Amid renewed trade and geopolitical uncertainty, the European stock market has seen declines, with the pan-European STOXX Europe 600 Index ending 0.98% lower. Despite these challenges, business activity in the eurozone remains positive, offering a glimmer of optimism for investors seeking opportunities in undervalued stocks. In this context, identifying stocks trading below their intrinsic value can be crucial for investors looking to capitalize on potential market inefficiencies and position...

Share buy-back launch puts Aktieselskabet Schouw (CPSE:SCHO) in focus Aktieselskabet Schouw (CPSE:SCHO) has moved into the spotlight after launching a share buy-back programme of up to DKK 240 million through 2026, a capital allocation decision that can influence both valuation and trading interest. See our latest analysis for Aktieselskabet Schouw. That buy-back announcement lands after a steady run in the share price, with a 30-day share price return of 4.67% and a 90-day share price return...

Event driven focus on Demant’s evolving platform Demant (CPSE:DEMANT) is refocusing around a comprehensive audio healthcare platform. The platform is built on custom chipsets, on device AI, and an integrated retail and diagnostics footprint that ties hardware, software, and clinical services together. See our latest analysis for Demant. At a DKK233.2 share price, Demant’s recent 1 month share price return of 8.97% and year to date share price return of 9.28% sit against a 1 year total...

The Board of Directors of Alm. Brand (CPSE:ALMB) has recommended an ordinary dividend of DKK 0.66 per share for the 2025 financial year, corresponding to a total payout of DKK 0.9b. See our latest analysis for Alm. Brand. At a share price of DKK18.16, Alm. Brand has had a mildly weaker recent patch, with a 1 month share price return of a 3.51% decline, even though its 1 year total shareholder return of 25.93% points to momentum that has built over a longer horizon. If this dividend news has...

With its stock down 12% over the past month, it is easy to disregard Zealand Pharma (CPH:ZEAL). However, a closer look...

Coloplast A/S' ( CPH:COLO B ) price-to-earnings (or "P/E") ratio of 33.6x might make it look like a strong sell right...

A.P. Møller - Mærsk (CPSE:MAERSK B) is structurally returning to its Red Sea Suez Canal route, resuming transits through the corridor despite ongoing regional security concerns. The change affects how Maersk routes a portion of its Asia Europe and related services, shifting some traffic back from longer alternative routes. This decision comes as other global carriers continue to use rerouting options around Africa in response to the same security risks. For you as an investor, this move...

The recent installation of the last turbine at Ørsted (CPSE:ORSTED) Greater Changhua 2b and 4 offshore wind farms in Taiwan has sharpened investor focus on how these Asia Pacific projects might influence the stock. See our latest analysis for Ørsted. Ørsted shares have gained momentum recently, with a 30 day share price return of 16.05% and a year to date share price return of 7.62%. This comes even though the 1 year total shareholder return is a 6.86% decline and the 5 year total shareholder...

If you are wondering whether Novozymes is attractively priced or looking stretched at today’s levels, you are in the right place for a clear, valuation focused rundown of the stock. The share price last closed at DKK 412.0, with returns of 2.6% over the past year and 25.2% over three years. Shorter term moves include a 2.4% decline over 7 days, a 1.8% gain over 30 days, and a 3.8% return year to date. Recent news coverage around Novozymes has largely centered on its role in specialty enzymes...

Why Pandora’s 2025 Guidance Has Grabbed Investor Attention Pandora (CPSE:PNDORA) has put fresh numbers on the table, guiding for a Q4 2025 EBIT margin of around 33.5% and full year EBIT of about DKK 7.8b, with a group margin near 24%. This earnings outlook, presented on the Q4 2025 guidance call, gives readers clearer visibility on profitability expectations at a time when the share price has faced pressure over the past year. See our latest analysis for Pandora. The guidance comes after a...

FLSmidth (CPSE:FLS) has been in focus after launching a share buy-back programme of up to DKK 1.4b, authorising the repurchase of as many as 4,600,000 shares, which is around 8% of its share capital. See our latest analysis for FLSmidth. The buy-back arrives after a strong run, with the 1-month share price return of 21.08% and year-to-date share price return of 18.39% adding to a 1-year total shareholder return of 48.45%. This indicates that momentum has been building over both shorter and...

Tryg (CPH:TRYG) has had a rough month with its share price down 1.6%. However, the company's fundamentals look pretty...

RIAS A/S ( CPH:RIAS B ) has announced that on 26th of January, it will be paying a dividend ofDKK26.00, which a...

To the annoyance of some shareholders, Pandora A/S ( CPH:PNDORA ) shares are down a considerable 26% in the last month...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Hove A/S ( CPH:HOVE ) shares have continued their recent momentum with a 27% gain in the last month alone. The annual...

Brd. Klee A/S ( CPH:KLEE B ) is about to trade ex-dividend in the next three days. The ex-dividend date generally...

Novo Nordisk A/S ( CPH:NOVO B ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...

Bavarian Nordic A/S has begun a shareholder-authorized buyback program as of January 7, 2026, allowing repurchases of up to 10% of its share capital on Nasdaq Copenhagen at prices within 10% of the prevailing market price, with the mandate running through December 31, 2026. This move to retire shares adds a new capital allocation element that could influence how investors view Bavarian Nordic’s earnings profile and ownership structure. We’ll now examine how this newly launched share...